论文部分内容阅读
目的:探究临床有效治疗妊娠期糖尿病的可靠方法。方法:对84例妊娠期糖尿病患者随机分为观察组(采用门冬胰岛素诺和锐进行治疗)和对照组(采用生物合成人胰岛素诺和灵R进行治疗)各42例,观察比较两组患者临床治疗后FPG、2Hppg、Hb Alc、胰岛素用量和达标时间。结果:在FPG、2Hppg、Hb Alc、胰岛素用量、达标时间等5项指标上观察组均明显的优于对照组,差异有统计学意义(P<0.05);总低血糖发生率观察组显著的低于对照组,差异有统计学意义(P<0.01)。结论:在临床针对妊娠期糖尿病患者采用门冬胰岛素进行治疗的临床优势明显,相关患者的临床指标水平更好,不良反应发生水平更低,是临床治疗妊娠期糖尿病的理想选择。
Objective: To explore a reliable clinical method for the treatment of gestational diabetes. Methods: Eighty-four patients with gestational diabetes mellitus were randomly divided into observation group (treated with insulin aspart noviru) and control group (treated with biosynthetic human insulin Novolin R) for 42 cases. Clinical treatment FPG, 2Hppg, Hb Alc, insulin dosage and time of compliance. Results: The observation group on FPG, 2Hppg, Hb Alc, the amount of insulin, the target time of five indicators were significantly better than the control group, the difference was statistically significant (P <0.05); the total incidence of hypoglycemia in the observation group was significantly Lower than the control group, the difference was statistically significant (P <0.01). Conclusions: The clinical advantages of using insulin aspart in clinical treatment of gestational diabetes patients are obvious. The clinical indexes of patients with related diseases are better and the incidence of adverse reactions is lower. It is an ideal choice for clinical treatment of gestational diabetes mellitus.